Medical Economics December 7, 2023
Public-private partnerships will crumble, hurting drug innovation and eventually patients, Republicans say.
High prescription drug prices are a target for a new federal program that could change drug licensing and accessibility rules.
Critics slammed the move as an attack on free market principles that will stifle drug research and innovation.
On Dec. 7, President Joe Biden announced “new actions to lower health care and prescription drug costs by promoting competition.” Those include having the U.S. Departments of Commerce and of Health and Human Services to explore using government authority to license inventions to another party, if the invention is made using taxpayer funds.
That power is known as “march-in authority” under the Bayh-Dole Act, and this would be the first...
Today's Sponsors
Today's Sponsor